Clinical and economic issues complicating cost-effectiveness evaluation of orphan diseases
Cost-effectiveness evaluation of orphan medicinal products is confronted with a large confidence interval on the incremental cost-effectiveness ratios (ICERs), or extremely high ICERs and therefore rejection of products for uptake in the health insurance package (coverage) by health authorities in E...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2017-05-01
|
| Series: | The EuroBiotech Journal |
| Online Access: | https://doi.org/10.24190/ISSN2564-615X/2017/02.04 |